{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:55:54Z","timestamp":1790484954026,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Neuroendocrine differentiation of prostate cancer (PCa) is a relatively frequent event,\ngenerally understudied, that carries important prognostic information. It is the most frequently observed\nduring the advanced stages of disease, when PCa has lost its sensitivity to androgen deprivation\ntherapy or to chemotherapy, moderate to diffuse bone metastatic spread dominates the imaging\nscenario and it is responsible for painful clinical symptomatology. However, evidences indicate that\nneuroendocrine differentiation is a progressive phenomenon that starts at the very early part of the\npathogenesis of cancer transformation contributing to it. Neuroendocrine tumor phenotypes have reduced\ncapability to secrete the prostate specific antigen (PSA) and therefore PSA does not represent\na reliable marker to follow-up neuroendocrine differentiation. Tumor progression may be monitored\nby measuring plasma concentration of neuroendocrine tumor markers, primarily chromogranin A and\nneuron-specific enolase. Several nuclear medicine tracers are available for studying different biochemical\nproperties of tumor cells with neuroendocrine differentiation. Single photon computed\nemission tomography (SPECT) with [111In-diethylenetriaminepentaacetic acid] ([111In-DTPA0])-\noctreotide (Octreoscan) has been extensively used in the past. However, the development of the\nchelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), which in comparison to\nDTPA allows higher affinity bindings for beta-emitting radionuclides and for somatostatin (SST)\nanalogues, and the increased availability of the Germanium-68\/Gallium-68 (68Ge\/68Ga)-generator,\nwhich enables positron emission tomography\/computed tomography (PET\/CT) imaging, have allowed\nthe synthesis of several PET tracers for different SST receptors. The receptor of the bombesin\/\ngastrin releasing peptide (GRP), which is overexpressed in PCa with neuroendocrine differentiation,\nalso represents an innovative research field with diagnostic and therapeutic applications\nthrough, respectively, positron and beta emitters. At the moment, however, we observe some discrepancy\nbetween the high number of preclinical studies and the small number of clinical studies,\nmost likely related to competing and, at the moment, more effective radiopharmaceuticals for imaging\nand for radiometabolic therapy, such PET\/CT with radiolabeled choline and prostate-specific\nmembrane antigene (PSMA)-ligands, the latter being labeled either with 68Ga for imaging or with\nLutetium-177 for therapy. Radium-223 dichloride has also been recently successfully introduced for\npalliative therapy of bone metastases in PCa. For these reasons, while the development of radiopharmaceuticals\nfor diagnosis and therapy (theranostics concept) of neuroendocrine differentiated\nPCa is scientifically stimulating, the ultimate clinical impact remains presently difficult to predict.\nSimilar effectiveness in comparison to other forms of diagnostic and radiometabolic radiopharmaceuticals\nthat have already gained convincing acceptance among referring clinicians needs to be\ndemonstrated.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471009666161229123126","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T07:28:41Z","timestamp":1489044521000},"page":"6-15","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer"],"prefix":"10.2174","volume":"10","author":[{"given":"Giampiero","family":"Giovacchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Riondato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ciarmiello","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto, 197, 19124 La Spezia,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471009666161229123126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/148785\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874471009666161229123126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:33:12Z","timestamp":1657279992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/148785\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471009666161229123126","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}